Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC18 (Telitacicept) in Rheumatoid Arthritis
NCT03016013Phase 3Completed
- Sponsor
- RemeGen
- Start
- Mar 2017
- Primary completion
- Nov 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of telitacicept in rheumatoid arthritis (RA), sponsored by RemeGen. Started Mar 2017; status: completed.
02
Drugs
telitacicept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03016013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03016013.